Tech Company Financing Transactions
OncoNano Medicine Funding Round
On 5/18/2018, OncoNano Medicine raised $11.7 million in Series A funding from Salem Partners and private investors.
Transaction Overview
Company Name
Announced On
5/18/2018
Transaction Type
Venture Equity
Amount
$11,700,000
Round
Series A
Investors
Salem Partners (Lead Investor) (John Dyett)
Proceeds Purpose
The funding will be used to support the company's continued clinical development of a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease indications such as cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5323 Harry Hines Blvd.
Dallas, TX 75390
USA
Dallas, TX 75390
USA
Phone
Website
Email Address
Overview
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. pH variability is a proven, simple and effective identifier of diseased tissue providing a foundation for the development of a broad range of highly targeted therapeutics and imaging agents.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Al Guillem
Chief Financial Officer
Matthew Head
President
Ravi Srinivasan
VP - Operations
Donald Kruppa
VP - R & D
Tian Zhao
VP - Regulatory Affairs
Kathy Rath
Browse more venture capital transactions:
Prev: 5/18/2018: DigitalTown venture capital transaction
Next: 5/18/2018: Decent venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs